Both trials demonstrated twice daily oral doses of nerandomilast (9 mg and 18 mg) significantly reduced the decline in forced vital capacity (FVC) from baseline at week 52, compared to placebo (adjusted mean change from baseline in FVC: FIBRONEER-IPF, -138.6 mL with nerandomilast 9 mg, -114.7 mL with nerandomilast 18 mg, -183.5 mL with placebo
A high-protein, high-fibre snack at this time can meaningfully prevent the spike-and-crash cycle that drives overeating at dinner
Most symptoms stabilize as you reach your steady-state dose, though keeping a symptom log helps you and your PlexusDx provider distinguish medication effects from your baseline post-surgical digestion
Because it slows digestion and alters hunger signaling in the brain, it has also become widely used off-label to treat clinical obesity and manage weight
This approach allows clinicians to personalize therapy based on individual metabolic pathways and genetic predispositions, maximizing weight loss and metabolic health outcomes without proportional price increases
Study: Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide
